When the Food and Drug Administration issues a declaratory order finding that a drug shortage is resolved, the effect on compounding pharmacies is immediate. The exception that lets 503A pharmacies and 503B outsourcing facilities compound a drug that is essentially a copy of a commercially available product exists only while that product sits on the FDA drug shortage list. Once the agency issues the order, the statutory basis for continuing to compound the drug disappears, regardless of the inventory on hand, the prescriptions pending, or the patients mid-course on a compounded formulation. The transition from lawful compounding to legal exposure can happen within a single business day.
The Shortage-List Exception Under Sections 503A and 503B
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. §§ 353a and 353b, generally prohibit a compounder from making a drug that is essentially a copy of a commercially available, FDA-approved product. The rule exists so pharmacies and outsourcing facilities cannot bypass the agency's approval process by mass-producing the same molecule outside it. Both statutes carve out an exception: a compounded drug identical or nearly identical to an approved product is not treated as a copy if the approved product appears on the FDA drug shortage list at the time of compounding, distribution, and dispensing. That 503A/503B shortage-list exception, not any general right to compound popular medications, is what permitted large-scale compounding of drugs like semaglutide and tirzepatide over the past several years.
What an FDA Declaratory Order Changes
FDA's shortage determinations are not informal announcements. The agency issues a declaratory order that identifies the specific drug, dosage form, and strength being removed from the list, and the order takes effect on the date it is issued. Tirzepatide injection products came off the shortage list by declaratory order on December 19, 2024. Semaglutide injection products followed on February 21, 2025. Both determinations were closely watched because they defined how much runway a compounding pharmacy gets once its shortage-list justification disappears, a question covered in depth for Compounding Semaglutide After the Shortage Delisting and for Tirzepatide Compounding: Enforcement Risk After the Shortage List. The same mechanics apply to any drug FDA removes from the list, not only GLP-1 products.
The Wind-Down Window After a Shortage Is Resolved
FDA has not adopted a fixed regulatory grace period that applies automatically every time a drug leaves the shortage list. In the tirzepatide and semaglutide determinations, the agency exercised enforcement discretion for a defined transition window: 60 days for state-licensed 503A pharmacies and 90 days for 503B outsourcing facilities, both running from the date of the declaratory order. Ordinary cGMP obligations for outsourcing facilities and USP 797/800 sterile-compounding standards continue to apply throughout the window, shortage or no shortage. Product compounded and dispensed before the deadline can generally still be used through its assigned beyond-use date, but new compounding after the window closes is a different question entirely. A pharmacy that keeps filling scripts past its enforcement-discretion deadline risks FDA action and invites the kind of state board compounding inspection that follows a complaint or a routine audit.
The end of a shortage does not erase the compounded product already on the shelf. It erases the legal basis for making more of it.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel once a drug they compound is removed from the FDA shortage list. Early legal intervention can confirm the exact wind-down deadline that applies to the specific drug and facility type, document the basis for any continued patient-specific compounding, and correct labeling or recordkeeping practices before an FDA inspection or state board complaint occurs. Delaying that review until a warning letter or 483 finding arrives narrows the pharmacy's options and can turn a compliance question into an enforcement matter.
How Health Law Alliance Can Help
Health Law Alliance represents 503A pharmacies and 503B outsourcing facilities navigating FDA shortage-list transitions, warning letter responses, and state board of pharmacy inquiries tied to compounded drug production. If your pharmacy compounds a drug that has recently left the FDA shortage list, contact us for a free, confidential consultation.
